Company Overview and News
Have you been paying attention to shares of Ligand Pharmaceuticals (LGND - Free Report) ? Shares have been on the move with the stock up 15.7% over the past month. LGND hit a new 52-week high of $195.17 in the previous session. Ligand Pharmaceuticals has gained 42.4% since the start of the year compared to the -0.4% move for the Medical sector and the -6.5% year-to-date return for its peer group.
Cerner Corporation’s (CERN - Free Report) wholly owned subsidiary, Cerner Government Services, Inc., recently signed an agreement with the Department of Veterans Affairs (VA). Cerner aims to facilitate care to the veteran community through VA’s efficient integrated network.
Cerner Corporation (CERN - Free Report) is an underperforming company in the MedTech space. Stiff competition and a soft first quarter of 2018 are major headwinds at the moment.
In a bid to make quality radiotherapy treatment readily accessible, Varian Medical Systems, Inc. (VAR - Free Report) recently announced a software technology training and education cooperation agreement with the Brazil Ministry of Health (MOH), and seven universities and science and technology institutions (ICTs) in Brazil. This will enable the company to fight cancer treatment in Brazil and across Latin America.
Investors have started mulling over the top bets of big investors like Bill Ackman, George Soros, Carl Icahn, David Tepper, Larry Robbins, Leon Cooperman, Daniel Loeb, David Einhorn and Stanley Druckenmiller, following the first-quarter release of 13F Forms. The group, often known as hedge funds and shifting composition, has outperformed the broad stock market this year after nearly a decade of underperformance.
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio. One such stock that you may want to consider dropping is Anika Therapeutics, Inc. (ANIK - Free Report) , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
DENTSPLY SIRONA (XRAY - Free Report) has underperformed the industryin the last six months. The company’s shares have lost 27.9% comparing unfavorably with the industry’s gain of 5.1%. The current level is also significantly lower than the S&P 500 index’s return of 5.3%.
On May 16, we issued an updated research report on Thermo Fisher Scientific, Inc. (TMO - Free Report) . Banking on several takeovers including Patheon and FEI acquisitions, this leading scientific instrument maker is rapidly ramping up its inorganic growth profile. The company’s strong focus on the emerging markets is also encouraging. The stock has a Zacks Rank #3 (Hold).
Shares of Abaxis, Inc. (ABAX - Free Report) skyrocketed soon after its acquisition news grabbed headlines. The stock jumped more than 16% yesterday following animal health company Zoetis Inc.’s (ZTS - Free Report) announcement to buy Abaxis for an approximate deal value of $2 billion.
Cerner Corporation’s (CERN - Free Report) integrated electronic health record (EHR) and revenue cycle management solutions have been recently picked by Crisp Regional Health, Inc. Post the announcement, Cerner’s stock rallied 2.9% to $59.97.
In a bid to replace the simple custom-made data warehouses with a unique industry-specific data model, Veeva Systems (VEEV - Free Report) recently introduced Veeva Nitro — a new model of commercial data warehouse for Life Sciences.
Investors certainly have to be happy with Genomic Health, Inc. (GHDX - Free Report) and its short term performance. After all, the stock has jumped by 16% in the past 4 weeks, and it is also above its 20 Day Simple Moving Average as well. This is certainly a good trend, but investors are probably asking themselves, can this positive trend continue for GHDX?
Baxter International Inc. (BAX - Free Report) recently announced FDA approval of the Spectrum IQ Infusion System with Dose IQ Safety Software in order to simplify EMR (Electronic Medical Record) administration for patients.
Fresenius Medical Care (FMS - Free Report) has had a dismal run on the bourses of late. Over the last three months, the company’s shares lost 6.4%, wider than the S&P 500 index’s fall of 0.2%.
Varian Medical Systems, Inc. (VAR - Free Report) is currently one of the top-performing stocks in the U.S. MedTech space. The company’s broad product spectrum, strong second-quarter fiscal 2018 results and a solid international foothold deserve a mention.
19h - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
20h - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
as of ET